Key result
Adding eGFR-derived renal dysfunction to the ESC algorithm improves 30-day mortality risk reclassification by ~18%.
Why the study?
Renal dysfunction influences outcomes after PE, but the incremental value of adding eGFR to the ESC prognostic model for predicting 30-day mortality was undetermined.
Does adding eGFR-defined renal dysfunction to the ESC prognostic model improve prediction of 30-day mortality in patients with acute pulmonary embolism?
Cohort (n=1,943)
Yes
Does adding eGFR-defined renal dysfunction to the ESC prognostic model improve prediction of 30-day mortality in patients with acute pulmonary embolism?
Effect estimate: OR 2.12 (95% CI 1.30-3.45)
Absolute Event Rate: 10.4% vs 3.9%
p-value: p=0.002
Adding eGFR-derived renal dysfunction to the ESC prognostic algorithm significantly improves risk stratification and reclassifies mortality risk in intermediate- and high-risk acute pulmonary embolism.
May improve 30-day mortality risk stratification in acute PE; leaves open prospective validation before ESC algorithm integration.
Background Renal dysfunction influences outcomes after pulmonary embolism (PE). We aimed to determine the incremental value of adding renal dysfunction, defined by estimated glomerular filtration rate (eGFR), on top of the European Society of Cardiology (ESC) prognostic model, for the prediction of 30-day mortality in acute PE patients, which in turn could lead to the optimization of acute PE management. Methods We performed a multicenter, non-interventional retrospective post hoc analysis based on a prospectively collected cohort including consecutive confirmed acute PE stratified per ESC guidelines. We first identified which of three eGFR formulae most accurately predicted death. Changes in global model fit, discrimination, calibration and reclassification parameters were evaluated with the addition of eGFR to the prognostic model. Results Among 1943 patients (mean age 67.3 (17.1), 50.4% women), 107 (5.5%) had died at 30 days. The 4-variable Modification of Diet in Renal Disease (eGFR MDRD4 ) formula predicted death most accurately. In total, 477 patients (24.5%) had eGFR MDRD4 < 60 ml/min. Observed mortality was higher for intermediate–low-risk and high-risk PE in patients with versus without renal dysfunction. The addition of eGFR MDRD4 information improved model fit, discriminatory capacity, and calibration of the ESC model. Reclassification parameters were significantly increased, yielding 18% reclassification of predicted mortality ( p < 0.001). Predicted mortality reclassifications across risk categories were as follows: 63.1% from intermediate–low risk to eGFR-defined intermediate–high risk, 15.8% from intermediate–high risk to eGFR-defined intermediate–low risk, and 21.0% from intermediate–high risk to eGFR-defined high risk. External validation in a cohort of 14,234 eligible patients from the RIETE registry confirmed our findings with a significant improvement of Harrell’s C index and reclassification parameters. Conclusion The addition of eGFR MDRD4 -derived renal dysfunction on top of the prognostic algorithm led to risk reclassification within the intermediate- and high-risk PE categories. The impact of risk stratification integrating renal dysfunction on therapeutic management for acute PE requires further studies.
No takes yet. Share an insight, caveat, or question.
Chopard et al. (2021) conducted a cohort in Acute pulmonary embolism (n=1,943). eGFRMDRD4 < 60 ml/min (Renal dysfunction) vs. eGFRMDRD4 ≥ 60 ml/min (Normal renal function) was evaluated on 30-day all-cause mortality (OR 2.12, 95% CI 1.30-3.45, p=0.002). The addition of eGFRMDRD4-derived renal dysfunction to the ESC prognostic algorithm improved 30-day mortality risk stratification, yielding an 18% reclassification of predicted mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: